Use your antibodies-online credentials, if available.
Overall, the available data depict a self-inhibitory feedback loop in which HBV, through HBx, increases the expression of miR (显示 MYLIP 抗体)-125a, that in turn interferes with expression of HBV surface antigen, thus repressing viral replication.
Those findings highlight the potential role of SIRT2 (显示 SIRT2 抗体) in HBV and HBV-mediated HCC (显示 FAM126A 抗体) by interaction with HBx.
HBXIP can modulate the etoposide sensitivity of MCF-7 cell lines.
deacetylation of MST1 mediated by HBXIP-enhanced HDAC6 results in MST1 degradation in a CMA manner in promotion of breast cancer growth.
HBXIP up-regulates YAP (显示 YAP1 抗体) expression via activating transcription factor c-Myb (显示 MYB 抗体) to facilitate the growth of hepatoma cells.
high level of expression of HBXIP is associated with the progression of non-small-cell lung cancer and may be a useful biomarker for poor prognostic evaluation and a potential molecular therapy target for patients with non-small-cell lung cancer
HBXIP is able to depress the gluconeogenesis in hepatoma cells by suppressing PCK1 (显示 PCK1 抗体) to promote hepatocarcinogenesis, involving miR (显示 MLXIP 抗体)-135a/FOXO1 (显示 FOXO1 抗体) axis and PI3K (显示 PIK3CA 抗体)/Akt (显示 AKT1 抗体)/p-FOXO1 (显示 FOXO1 抗体) pathway.
we conclude that the oncoprotein HBXIP contributes to the abnormal lipid metabolism in breast cancer
HBXIP can function as a mediator protein for DNA damage response signals to activate the G2/M checkpoint to maintain genome integrity and prevent cell death.
promotes cisplatin resistance and regulates CD147 via Sp1 (显示 PSG1 抗体) in ovarian cancer
The mRNA levels of ACSL1 (显示 Acsl1 抗体) were positively associated with those of HBXIP in clinical breast cancer tissues. Thus, we conclude that the oncoprotein HBXIP is able to up-regulate ACSL1 (显示 Acsl1 抗体) through activating the transcriptional factor Sp1 (显示 PSG1 抗体) in breast cancer.
This gene encodes a protein that specifically complexes with the C-terminus of hepatitis B virus X protein (HBx). The function of this protein is to negatively regulate HBx activity and thus to alter the replication life cycle of the virus.
hepatitis B virus x interacting protein
, hepatitis B virus x-interacting protein
, Hepatitis B virus X-interacting protein
, HBV X-interacting protein homolog
, HBX-interacting protein homolog
, hepatitis B virus X-interacting protein homolog
, late endosomal/lysosomal adaptor and MAPK and MTOR activator 5
, ragulator complex protein LAMTOR5
, HBV X-interacting protein
, HBx-interacting protein
, hepatitis B virus x-interacting protein (9.6kD)
, Hepatitis B virus X-interacting protein homolog